2-methoxyestradiol

02/01/2003 - "The exact mechanism of action of 2-methoxyestradiol is still unclear, but it has been shown to be effective in preventing tumor growth in a variety of cell lines. "
04/15/2010 - "2-Methoxyestradiol (2ME), an end-metabolite of 17beta-estradiol, is an antiproliferative agent that is currently being tested in clinical trials for cancer treatment. "
07/01/2006 - "SAR studies of 2-methoxyestradiol and development of its analogs as probes of anti-tumor mechanisms."
08/01/2004 - "Previous studies also showed that 2-methoxyestradiol (2-ME), an endogenous non-toxic estrogenic metabolite, induces the stabilization of the wild-type p53 protein in human cancer cells posttranscriptionally. "
02/01/2015 - "2-Methoxyestradiol (2ME) is a promising anti-cancer agent that disrupts the integrity and dynamics of the spindle network. "

03/21/2006 - "2-Methoxyestradiol (2-ME(2)), a promising anticancer drug, induces growth arrest and apoptosis in various androgen-dependent (LNCaP) and -independent (DU145 and PC-3) prostate cancer cell lines. "
03/21/2006 - "Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways."
10/01/2004 - "Effects of 2-methoxyestradiol on proliferation, apoptosis and PET-tracer uptake in human prostate cancer cell aggregates."
01/01/2004 - "Here we investigated the molecular mechanism by which 2-methoxyestradiol (2-ME) effectively sensitizes a human prostate cancer cell line, PC3, to Fas-mediated apoptosis. "
01/01/2004 - "The molecular mechanism of sensitization to Fas-mediated apoptosis by 2-methoxyestradiol in PC3 prostate cancer cells."

01/01/2009 - "2-Methoxyestradiol and multidrug resistance: can 2-methoxyestradiol chemosensitize resistant breast cancer cells?"
04/01/2006 - "Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells."
01/15/2005 - "Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer."
11/01/2000 - "SULT1A1 catalyzes 2-methoxyestradiol sulfonation in MCF-7 breast cancer cells."
04/01/2012 - "Injectable implant would be a potential way for 2-methoxyestradiol (2-ME) for the therapy of breast cancer because of its water-insolubility, short half-life, and low oral bioavailability. "

01/01/2013 - "Furthermore, the hypoxia-inducible factor (HIF-1α) inhibitor 2-methoxyestradiol (2-ME2) decreased the activity of PKC by a specific pathway. "
10/01/2012 - "Although not statistically significant, a trend toward lower gene expression of hypoxia inducible factor-1α was seen in mice receiving 2-methoxyestradiol compared to placebo (p = 0.0625). "
10/01/2012 - "We investigated the ability of 2-methoxyestradiol to modulate the hypoxia response in a mouse model of bladder obstruction. "
10/01/2012 - "2-Methoxyestradiol is a natural derivative of 17β-estradiol and is currently used as an oncologic agent for its ability to regulate the hypoxia pathway. "
12/11/2011 - "Hypoxia stimulates the production of the angiogenesis inhibitor 2-methoxyestradiol by swine granulosa cells."

10/15/2007 - "Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma."
04/01/2006 - "It is concluded that lower concentrations of 2-methoxyestradiol can induce differentiation of bone marrow CD138+ cells from multiple myeloma patients."
05/01/2003 - "Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays."
12/01/2002 - "Promising preclinical activity of 2-methoxyestradiol in multiple myeloma."
09/15/2002 - "2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells."